Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2015

View Archived Issues

Researchers create first synthetic vascular repair graft composed of three layers

New safety data on PAT-SM6 in multiple myeloma patients

Brickell Biotech holds financing round, begins study of BBI-4000

BP-2001 reprograms intestinal cells into insulin-secreting cells in diabetes model

FDA to review sNDA for psoriasis candidate tofacitinib

Eisai updates on its Alzheimer's disease collaboration with Biogen Idec

EMA grants orphan drug status to Theravectys vaccine for ATL/L

QR Pharma and Rockefeller University collaborate to test Posiphen in HD models

Actavis to divest rights to respiratory portfolio in U.S. and Canada to AstraZeneca

Akaal Pharma reports data from phase I trial of AKP-11 in psoriasis

Isis Pharmaceuticals earns milestone payment from Biogen Idec for advancing ISIS-BIIB4Rx

UCB reports topline data from phase III program of Neupro in Parkinson's disease

Sanofi targets U.S. Lyxumia submission and LixiLan filings

Bristol-Myers Squibb discloses new IDO inhibitors

Universidad de Alcala patents treatments for leishmania and/or PTP-1B-related diseases

The University of Copenhagen patents iGluR antagonists

Inhibitors for mutant IDH2 disclosed by Agios Pharmaceuticals

Valeant amends Dendreon stalking horse asset purchase agreement

Allergan patent reports FPR2 modulators

RXi Pharmaceuticals acquires Samcyprone from Hapten Pharmaceuticals

CrystalGenomics' polmacoxib approved in South Korea for osteoarthritis

Daiichi Sankyo starts Asian phase III trial program for mirogabalin

FDA advisory committee sets March date to discuss Breo Ellipta filing

FDA approves Lucentis for diabetic retinopathy in patients with diabetic macular edema

Pfizer agrees to acquire Hospira

European Commission approves Velcade for mantle cell lymphoma

GSK files for E.U. approval of eltrombopag for treatment of chronic ITP in children

Daiichi Sankyo launches Savaysa in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...